Albany Molecular Research (AMRI) Misses Q4 EPS by 14c; Guides Below the Street

Albany Molecular Research (NASDAQ: AMRI) reported Q4 EPS of $0.34, $0.14 worse than the analyst estimate of $0.48. Revenue for the quarter came in at $191.3 million versus the consensus estimate of $221.3 million.

GUIDANCE:

Albany Molecular Research sees FY2017 EPS of $1.08-$1.20, versus the consensus of $1.30. Albany Molecular Research sees FY2017 revenue of $710-740 million, versus the consensus of $763.3 million.

For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c